Search clinical trials for: Influenza A/H5N1 Vaccine

Total 1420 results

University of Rochester
National Institutes of Health (NIH)

Withdrawn

Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children (H1N1Children)

2009 H1N1 Influenza

United States
PATH
Institute of Experimental Medicine, Russia; Research Institute of Influenza...

Completed

Immunogenicity of H5N1 Vaccine Following H5N2

Influenza Vaccine

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults

Orthomyxoviridae Infections | Pandemic Influenza | Influenza A Virus Infection

Belgium
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children

Influenza | Orthomyxoviridae Infections | Influenza A Virus Infection

Thailand
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
Chiltern Pesquisa Clinica Ltda

Completed

Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors

H1N1 Influenza Virus | Invasive Solid Tumors

Brazil
Green Cross Corporation

Completed

A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine

Influenza Infection
Masonic Cancer Center, University of Minnesota

Terminated

Influenza Vaccine Post Allogeneic Transplant

Hematologic Malignancy | Hematopoietic Stem Cell Transplant

United States
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above

Influenza

Germany
National Institute of Allergy and Infectious Diseases...

Completed

A/H5N1in Adult - Aventis

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Swine-origin A/H1N1 Influenza Vaccines in Healthy Europeans Children Aged 6 to 35 Months

Influenza | Swine-origin A/H1N1 Influenza

Finland
French National Agency for Research on AIDS and...
GlaxoSmithKline

Completed

Clinical Trial to Evaluate the Immunogenicity and Safety of an Adjuvanted A(H1N1)v Influenza Vaccine and a Non-adjuvanted A(H1N1)v Influenza Vaccine in HIV-infected Patients (ANRS 151 Hifluvac)

HIV Infections

France
National Institute of Allergy and Infectious Diseases...

Completed

Open Label Evaluation of H5N1 Vaccine at Vaccine Manufacturing Facilities

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Inactivated Influenza A/H5N1 Vaccine in the Elderly

Influenza

United States
National Taiwan University Hospital

Unknown

Antibody Titer Analysis After H1N1 Vaccination in Pediatric Haemato-oncology Patients

Serology Analysis | Novel H1N1 Influenza Vaccination | Pediatric Haemato-oncology Patients

Taiwan
Seqirus
Novartis Vaccines

Completed

Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)

Influenza

United States, Germany
Novartis Vaccines

Completed

Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two Monovalent H5N1 Influenza Vaccines Containing 2 Doses of H5N1 Influenza Antigen, in Non-elderly Adult and Elderly Subjects

Pandemic H5N1 Influenza

Poland, Turkey
Centers for Disease Control and Prevention

Unknown

Inactivated Influenza A/H5N1 Vaccine in Adult Subjects at Risk of Occupational Exposure to Live H5N1 Viruses

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

A/H5N1 Vaccine in Healthy Children Aged 2-9 Years

Influenza

United States
Adimmune Corporation

Completed

Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults

Pandemic Influenza

Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

Influenza

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 Vaccination With and Without AS03: Systems Biology Analysis

Influenza

United States
GlaxoSmithKline

Completed

A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64

Influenza

Canada
Emergent BioSolutions

Completed

Safety and Immunogenicity of Replication-Competent Adenovirus 4-vectored Vaccine for Avian Influenza H5N1

Influenza | Bird Flu

United States
GlaxoSmithKline

Completed

Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure

Influenza | Influenza Vaccines

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Inactivated Swine-Origin A/H1N1 Influenza Vaccines in Healthy European Subjects Aged 3 to 17 Years

Influenza | Swine-origin A/H1N1 Influenza

Finland
GlaxoSmithKline

Completed

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults

Influenza

United States
University of Oxford

Completed

Swine Flu (Novel Influenza A H1N1) Vaccine Study

Influenza

United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Open-Label Study of H5 Vaccine in Participants of Protocol 04-077

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

St. Jude Open Label H5 Trial

Influenza

United States
Sanofi

Completed

A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
GlaxoSmithKline

Completed

A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age

Influenza

Taiwan, Thailand
National Institute of Allergy and Infectious Diseases...

Completed

H5 Booster After a Two Dose Schedule

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

H5N1 (Clade 2) Vaccination of Adults and Elderly

Influenza

United States
National Institute of Allergy and Infectious Diseases...

Completed

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity & Safety of GSK's Influenza Vaccine 1557484A Given to Adults Aged ≥18 Years

Influenza

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Different Formulations of an A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly

Influenza | Swine-origin A/H1N1 Influenza

United States
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine

Influenza

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of an Intramuscular A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine in Children

Influenza | Orthomyxoviridae Infections | Orthomyxovirus Infections

Finland
Sinovac Biotech Co., Ltd

Completed

Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults

Influenza

China
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Adults and Elders

Influenza

Taiwan
Adimmune Corporation

Completed

Immunogenicity and Safety of Influenza Virus Vaccine, AdimFlu-S (A/H1N1), in Pediatric Population

Influenza

Taiwan
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age

Pandemic Influenza

Switzerland, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Tolerability and Safety of One or Two Doses of an Adjuvanted Swine-origin A H1N1 Influenza Vaccine in Healthy Subjects 18 or More Years of Age Both Vaccinated and Not Yet Vaccinated Against Seasonal Influenza 2009/10

Pandemic Influenza Disease

Italy
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Dominican Republic, Belgium, Germany
Novartis Vaccines

Completed

Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age

Pandemic Influenza

Netherlands, Belgium, Chile, Dominican Republic, Germany
Centers for Disease Control and Prevention, China

Unknown

Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month

Influenza | Swine-origin A/H1N1 Influenza

China
National Institute of Allergy and Infectious Diseases...

Completed

Higher Dose Intradermal H5 Vaccine

Influenza

United States
University of Rochester
National Institutes of Health (NIH)

Completed

Effects of Age on Response to the 2009 H1N1 Virus Vaccine

2009 H1N1 Influenza Virus

United States

3

Subscribe